Suchergebnisse
10
Alles
RetinalGenix Technologies Breakthrough in Real-Time 24/7 Remote Ocular Monitoring
20. Februar 2025 06:30 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES BREAKTHROUGH IN REAL-TIME 24/7 REMOTE OCULAR MONITORING
High-Resolution Retinal Imaging Using Both Near Infrared And Green Modes
ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings
04. Februar 2025 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 04, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Macular Degeneration Treatment Market Size is Projected to Reach USD 18.59 Billion by 2033, Growing at a CAGR of 7.06%: Straits Research
29. Januar 2025 10:25 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The eye’s macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision...
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer
07. Januar 2025 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Intraocular Lens (IOL) Global Market Overview 2021-2023 and Forecasts 2024-2030
03. Oktober 2024 10:20 ET
|
Research and Markets
Dublin, Oct. 03, 2024 (GLOBE NEWSWIRE) -- The "Intraocular Lens (IOL) - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global Intraocular Lens (IOL) market...
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
13. September 2024 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight
10. September 2024 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
05. September 2024 10:52 ET
|
Boehringer Ingelheim
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record |...
Eclipse Life Sciences Initiates Phase 2 Study for Novel Ophthalmology Steroid Implant for Diabetic Macular Edema (DME)
12. August 2024 07:45 ET
|
Eclipse Life Sciences
RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies...
Age-Related Macular Degeneration (AMD) Market Forecast Report by Disease Type, Product, Distribution Channel, Countries, and Company Analysis: 2024-2032
08. August 2024 06:55 ET
|
Research and Markets
Dublin, Aug. 08, 2024 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration Market Forecast Report by Disease Type Product Distribution Channel Countries and Company Analysis, 2024-2032" report...